Ocular Therapeutix Inc. (OCUL)

NASDAQ: OCUL · Real-Time Price · USD

8.55

0.25 (3.01%)

At close: May 01, 2025, 3:59 PM

3.01% (1D)

Bid	8.37
Market Cap	1.36B
Revenue (ttm)	63.66M
Net Income (ttm)	-193.51M
EPS (ttm)	-1.22
PE Ratio (ttm)	-7.01
Forward PE	-6.45
Analyst	Buy

Ask	8.92
Volume	1,212,116
Avg. Volume (20D)	1,523,034
Open	8.28
Previous Close	8.30
Day's Range	8.07 - 8.69
52-Week Range	4.79 - 11.78
Beta	1.49

About OCUL

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammati...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 25, 2014

Employees 274

Stock Exchange NASDAQ

Ticker Symbol OCUL

Website https://www.ocutx.com

Full Company Profile

Analyst Forecast

According to 10 analyst ratings, the average rating for OCUL stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 98.71% from the latest price.

Stock Forecasts

Next Earnings Release

Ocular Therapeutix Inc. is scheduled to release its earnings on May 5, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+11.24%

Ocular Therapeutix shares are trading higher after... Unlock content with Pro Subscription

1 month ago

-16.95%

Ocular Therapeutix shares are trading lower after the company reported worse-than-expected Q4 financial results.

News

1 month ago · fool.com

Why Ocular Therapeutix Was Bumping Higher This Week

The market was seeing Ocular Therapeutix (OCUL -6.52%) very positively this week, and that sunny view pushed the company's stock higher.

1 month ago · benzinga.com

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Needham initiated coverage on Ocular Therapeutix Inc OCUL, noting the company's lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular degeneration (we...

1 month ago · seekingalpha.com

Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential

Ocular Therapeutix focuses on Axpaxli, a long-acting wet AMD therapy administered every 6-12 months. Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has ...

1 month ago · zacks.com

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.28 per share a year ago.